Trial reportEuropean radiology2024
Evaluation of standard breast ultrasonography by adding two-dimensional and three-dimensional shear wave elastography: a prospective, multicenter trial.
Trial report in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Understanding and targeting the tumour matrisome.Nature reviews. Clinical oncology · 2026Review
- Qualitative shear wave elastography in malignant breast lesions: predictive factors associated with false-negative findings and their biological characteristics.Quantitative imaging in medicine and surgery · 2026Article
- Dual-mode 3D shear wave elastography with qualitative and quantitative assessment improves diagnosis of inguinal lymph node metastasis.Quantitative imaging in medicine and surgery · 2026Article
- Predictive value of elastography (Shear-Wave and Elasticity Index) in differentiating benign from malignant breast lesions: a retrospective study in Peru.Radiology and oncology · 2026Observational
- The utilization of CEUS and SWE for predicting pathological complete response to neoadjuvant chemotherapy for invasive breast cancer.Scientific reports · 2026Article
- Ultrasound Elastography and Tonometry as Predictive Tools for Capsular Contracture After Breast Implant Surgery: Over a 12-Month Prospective Study.Journal of clinical medicine · 2025Article
- A combined clinical-ultrasound radiomics model for differentiating benign and malignant BI-RADS category 4 breast masses.American journal of translational research · 2025Article
- Ultrasound elastography: advances and challenges in early detection of breast cancer.Frontiers in oncology · 2025Review
- Assessing Fat Grafting in Breast Surgery: A Narrative Review of Evaluation Techniques.Journal of clinical medicine · 2024Review
- Evaluating breast ultrasonography as a complementary diagnostic method in girls with central precocious puberty.Pediatric radiology · 2024Article
- Breast elastography-ready for prime time?European radiology · 2024Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
22 authors at 10 institutions in 1 country.
Funding
Abstract
objectiveTo reduce the number of biopsies performed on benign breast lesions categorized as BI-RADS 4-5, we investigated the diagnostic performance of combined two-dimensional and three-dimensional shear wave elastography (2D + 3D SWE) with standard breast ultrasonography (US) for the BI-RADS assessment of breast lesions.
methodsA total of 897 breast lesions, categorized as BI-RADS 3-5, were subjected to standard breast US and supplemented by 2D SWE only and 2D + 3D SWE analysis. Based on the malignancy rate of less than 2% for BI-RADS 3, lesions assessed by standard breast US were reclassified with SWE assessment.
resultsAfter standard breast US evaluation, 268 (46.1%) participants underwent benign biopsies in BI-RADS 4-5 lesions. By using separated cutoffs for upstaging BI-RADS 3 at 120 kPa and downstaging BI-RADS 4a at 90 kPa in 2D + 3D SWE reclassification, 123 (21.2%) participants underwent benign biopsy, resulting in a 54.1% reduction (123 versus 268).
conclusionCombining 2D + 3D SWE with standard breast US for reclassification of BI-RADS lesions may achieve a reduction in benign biopsies in BI-RADS 4-5 lesions without sacrificing sensitivity unacceptably. CLINICAL RELEVANCE STATEMENT: Combining 2D + 3D SWE with US effectively reduces benign biopsies in breast lesions with categories 4-5, potentially improving diagnostic accuracy of BI-RADS assessment for patients with breast lesions.
trial registrationChiCTR1900026556 KEY POINTS: • Reduce benign biopsy is necessary in breast lesions with BI-RADS 4-5 category. • A reduction of 54.1% on benign biopsies in BI-RADS 4-5 lesions was achieved using 2D + 3D SWE reclassification. • Adding 2D + 3D SWE to standard breast US improved the diagnostic performance of BI-RADS assessment on breast lesions: specificity increased from 54 to 79%, and PPV increased from 54 to 71%, with slight loss in sensitivity (97.2% versus 98.7%) and NPV (98.1% versus 98.7%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.